

Contents

1 Targeted Therapy for Metastatic Renal Cell Carcinoma: Introduction.....	1
Ronald M. Bukowski, Robert A. Figlin, and Robert J. Motzer	
2 Renal Cell Carcinoma: Pathologic and Molecular Assessment of Targets	15
Ferran Algaba	
3 Genomic Assessment of Renal Cancer	39
Stephen M. Keefe, W. Kimryn Rathmell, and Katherine L. Nathanson	
4 VHL and HIF in Clear Cell Renal Cell Carcinoma: Molecular Abnormalities and Potential Clinical Applications	57
Lucy Gossage	
5 PBRM1: A Critical Subunit of the SWI/SNF Chromatin Remodeling Complex	111
Chung-Han Lee, Can G. Pham, and James J. Hsieh	
6 Sporadic RCC: Abnormalities in Histone-Modifying Genes.....	153
Ruhee Dere and Thai H. Ho	
7 Genetic Heterogeneity in Renal Cell Carcinoma: Clinical Implications?	167
Susan A. J. Vaziri, Mahrukh K. Ganapathi, and Ram N. Ganapathi	
8 First-Generation Tyrosine Kinase Inhibitors: Clinical Results.....	177
Han Hsi Wong and Tim Eisen	
9 Second-Generation Tyrosine Kinase Inhibitors (Pazopanib) in Renal Cell Carcinoma: Current Status.....	207
Linda Cerbone and Cora N. Sternberg	

10	Third-Generation TKIs (Axitinib, Tivozanib) in RCC: Enhanced Efficacy and Diminished Toxicity?	217
	Hui Zhu and Brian I. Rini	
11	Anti-VEGF and VEGFR Monoclonal Antibodies in RCC	237
	Bernard Escudier and Laurence Albiges	
12	PI3-kinase, Akt, and mTOR Inhibitors in RCC	253
	Daniel C. Cho and James W. Mier	
13	Carbonic Anhydrase IX and Monoclonal Antibody G250: Relevance as a Clinical and Biologic Target in Renal Cell Carcinoma	263
	Egbert Oosterwijk, Otto C. Boerman, Jeannette C. Oosterwijk-Wakka, Wim J. Oyen, and Peter F.A. Mulders	
14	EGFR and HER2: Relevance in Renal Cell Carcinoma	285
	Sarathi Kalra and Eric Jonasch	
15	The Role of Hepatocyte Growth Factor Pathway Signaling in Renal Cell Carcinoma	303
	Fabiola Cecchi, Young H. Lee, Benedetta Peruzzi, Jean-Baptiste Lattouf, and Donald P. Bottaro	
16	Development of Resistance to Targeted Therapy: Preclinical Findings and Clinical Relevance	319
	James W. Mier, Rupal S. Bhatt, David J. Panka, and Michael B. Atkins	
17	Development of Combination Therapy with Targeted Agents	349
	C. Lance Cowey and Thomas E. Hutson	
18	Side Effects of Targeted Therapy	377
	Luis León, Luis Miguel Antón-Aparicio, Emilio Esteban-González, Martin Lázaro-Quintela, and Sergio Vázquez Estevez	
19	The Role of Targeted Therapy in Special Populations	417
	James M. G. Larkin and Martin E. Gore	
20	Immunotherapy: The Current Role of Cytokines	441
	Mayer Fishman	
21	Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC	469
	Alexandra S. Bailey and David F. McDermott	
22	Vaccines in RCC: Clinical and Biological Relevance	483
	Devin B. Lowe, James H. Finke, Jorge A. Garcia, and Walter J. Storkus	

23	Development and Incorporation of Biomarkers in RCC Therapeutics	527
	Sumanta K. Pal and Robert A. Figlin	
24	Molecularly Targeted Staging Strategies in Renal Cell Carcinoma	541
	Steven G. Koopman, Ali-Reza Sharif-Afshar, Robert A. Figlin, and Hyung L. Kim	
25	Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma	555
	Nimira Alimohamed, Toni K. Choueiri, and Daniel Y.C. Heng	
26	The Role of Advocacy in Renal Cell Carcinoma	569
	William P. Bro and Paul Larson	
	Index.....	601

Renal Cell Carcinoma

Molecular Targets and Clinical Applications

Bukowski, R.; Figlin, R.A.; Motzer, R. (Eds.)

2015, XVIII, 613 p. 50 illus., 41 illus. in color., Hardcover

ISBN: 978-1-4939-1621-4